MMI0 Stock Overview
A clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
MEI Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.20 |
| 52 Week High | US$11.40 |
| 52 Week Low | US$3.58 |
| Beta | 0.92 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -63.79% |
| 3 Year Change | -93.14% |
| 5 Year Change | -93.84% |
| Change since IPO | -96.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| MMI0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | -3.5% |
| 1Y | -63.8% | -10.2% | 13.6% |
Return vs Industry: MMI0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: MMI0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| MMI0 volatility | |
|---|---|
| MMI0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: MMI0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MMI0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 102 | David Urso | meipharma.com |
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.
MEI Pharma, Inc. Fundamentals Summary
| MMI0 fundamental statistics | |
|---|---|
| Market cap | €44.15m |
| Earnings (TTM) | -€33.73m |
| Revenue (TTM) | €52.34m |
0.8x
P/S Ratio-1.3x
P/E RatioIs MMI0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MMI0 income statement (TTM) | |
|---|---|
| Revenue | US$58.77m |
| Cost of Revenue | US$0 |
| Gross Profit | US$58.77m |
| Other Expenses | US$96.65m |
| Earnings | -US$37.87m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.68 |
| Gross Margin | 100.00% |
| Net Profit Margin | -64.44% |
| Debt/Equity Ratio | 0% |
How did MMI0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/16 08:08 |
| End of Day Share Price | 2023/04/18 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MEI Pharma, Inc. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephen V. Byrne | BofA Global Research |
| Jonathan Aschoff | Brean Capital |
| Gene Mack | Brean Capital |